Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

282 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis.
Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le Maulf F, Peter N, Kearon C; RE-COVER II Trial Investigators. Schulman S, et al. Among authors: kakkar ak. Circulation. 2014 Feb 18;129(7):764-72. doi: 10.1161/CIRCULATIONAHA.113.004450. Epub 2013 Dec 16. Circulation. 2014. PMID: 24344086 Free article. Clinical Trial.
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Lee AY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Lee AY, et al. Among authors: kakkar ak. N Engl J Med. 2003 Jul 10;349(2):146-53. doi: 10.1056/NEJMoa025313. N Engl J Med. 2003. PMID: 12853587 Free article. Clinical Trial.
A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement.
Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Muehlhofer E, Dierig C, Misselwitz F, Kälebo P; ODIXa-HIP Study Investigators. Eriksson BI, et al. Among authors: kakkar ak. Circulation. 2006 Nov 28;114(22):2374-81. doi: 10.1161/CIRCULATIONAHA.106.642074. Epub 2006 Nov 20. Circulation. 2006. PMID: 17116766 Clinical Trial.
Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
Agnelli G, Gallus A, Goldhaber SZ, Haas S, Huisman MV, Hull RD, Kakkar AK, Misselwitz F, Schellong S; ODIXa-DVT Study Investigators. Agnelli G, et al. Among authors: kakkar ak. Circulation. 2007 Jul 10;116(2):180-7. doi: 10.1161/CIRCULATIONAHA.106.668020. Epub 2007 Jun 18. Circulation. 2007. PMID: 17576867 Clinical Trial.
Treatment of venous thromboembolism in cancer patients.
Petralia GA, Kakkar AK. Petralia GA, et al. Among authors: kakkar ak. Semin Thromb Hemost. 2007 Oct;33(7):707-11. doi: 10.1055/s-2007-991539. Semin Thromb Hemost. 2007. PMID: 18000799 Review.
Recommendations on biosimilar low-molecular-weight heparins.
Harenberg J, Kakkar A, Bergqvist D, Barrowcliffe T, Casu B, Fareed J, Mismetti P, Ofosu FA, Raake W, Samama M, Schulman S; Subcommittee on Control of Anticoagulation of the SSC of the ISTH. Harenberg J, et al. J Thromb Haemost. 2009 Jul;7(7):1222-5. doi: 10.1111/j.1538-7836.2009.03349.x. Epub 2009 Mar 23. J Thromb Haemost. 2009. PMID: 19323788 Free article.
282 results